CoQ10 Effects on MDM Liver Fat Via FibroTouchI.
ConditionMitochondrial Diabetes
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-70
SponsorThe 95th Hospital of Putian，Putian, Fujian, China
About this trial
Mitochondrial diabetes mellitus (MDM) is a rare subtype of diabetes caused by mitochondrial dysfunction, often accompanied by hepatic steatosis. Coenzyme Q10 (CoQ10), a key electron carrier and antioxidant, may improve mitochondrial function and lipid metabolism. This prospective study aims to evaluate the effect of 12-week CoQ10 supplementation (300 mg/day) on liver fat content (assessed by FibroTouch CAP ) in MDM patients with m.3243A\>G mutation. An exploratory case-control design will compare baseline characteristics among MDM patients, type 1 diabetes patients, and healthy controls. This study is the first to explore the link between mitochondrial defects and hepatic fat accumulation specifically in MDM, and to test CoQ10 as a potential therapy, offering new insights for both MDM and MAFLD management.
Eligibility criteria
Qualifiers
Confirmed as a carrier of the mitochondrial DNA m.3243A>G mutation through genetic testing;
Meeting the diagnostic criteria for diabetes (WHO 1999 diagnostic criteria);
Aged between 18 and 70 years;
Willing to participate and having signed the informed consent form.
Disqualifiers
Type 1 or type 2 diabetes (not caused by mitochondrial gene mutations);
Comorbid with viral hepatitis, drug-induced hepatitis, alcoholic liver disease, Wilson's disease, or other specific diseases that can lead to fatty liver;
Severe cardiac, pulmonary, or renal insufficiency;
Pregnant or lactating women;
Trial design
Treatments tested in this trial
- Coenzyme Q10 (drug)
- Only undergo baseline assessments without intervention.
- Only undergo baseline assessments without intervention.
Treatment groups
30 Participants
are divided into 3 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov